HomeCompareIMTXW vs DGRO

IMTXW vs DGRO: Dividend Comparison 2026

IMTXW yields 333333.33% · DGRO yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IMTXW wins by $8.099219044190773e+31M in total portfolio value
10 years
IMTXW
IMTXW
● Live price
333333.33%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.099219044190773e+31M
Annual income
$80,944,421,463,343,720,000,000,000,000,000,000,000.00
Full IMTXW calculator →
DGRO
iShares Core Dividend Growth ETF
● Live price
2.13%
Share price
$68.98
Annual div
$1.47
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.6K
Annual income
$239.96
Full DGRO calculator →

Portfolio growth — IMTXW vs DGRO

📍 IMTXW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIMTXWDGRO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IMTXW + DGRO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IMTXW pays
DGRO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMTXW
Annual income on $10K today (after 15% tax)
$28,333,333.33/yr
After 10yr DRIP, annual income (after tax)
$68,802,758,243,842,160,000,000,000,000,000,000,000.00/yr
DGRO
Annual income on $10K today (after 15% tax)
$181.24/yr
After 10yr DRIP, annual income (after tax)
$203.97/yr
At 15% tax rate, IMTXW beats the other by $68,802,758,243,842,160,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMTXW + DGRO for your $10,000?

IMTXW: 50%DGRO: 50%
100% DGRO50/50100% IMTXW
Portfolio after 10yr
$4.0496095220953863e+31M
Annual income
$40,472,210,731,671,860,000,000,000,000,000,000,000.00/yr
Blended yield
99.94%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMTXW buys
0
DGRO buys
0
No recent congressional trades found for IMTXW or DGRO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIMTXWDGRO
Forward yield333333.33%2.13%
Annual dividend / share$2.00$1.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$8.099219044190773e+31M$31.6K
Annual income after 10y$80,944,421,463,343,720,000,000,000,000,000,000,000.00$239.96
Total dividends collected$8.098906375781879e+31M$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: IMTXW vs DGRO ($10,000, DRIP)

YearIMTXW PortfolioIMTXW Income/yrDGRO PortfolioDGRO Income/yrGap
1← crossover$33,344,033$33,333,333.33$11,293$213.22+$33.33MIMTXW
2$103,911,171,366$103,875,493,250.26$12,730$217.32+$103911.16MIMTXW
3$302,644,656,190,810$302,533,471,237,448.00$14,326$221.10+$302644656.18MIMTXW
4$823,817,797,451,856,400$823,493,967,669,732,100.00$16,098$224.56+$823817797451.84MIMTXW
5$2,095,836,995,961,804,000,000$2,094,955,510,918,530,000,000.00$18,064$227.74+$2095836995961804.00MIMTXW
6$4,983,251,920,823,462,000,000,000$4,981,009,375,237,783,000,000,000.00$20,246$230.65+$4983251920823461888.00MIMTXW
7$11,073,835,968,753,321,000,000,000,000$11,068,503,889,198,040,000,000,000,000.00$22,666$233.30+$1.1073835968753322e+22MIMTXW
8$22,999,277,308,531,336,000,000,000,000,000$22,987,428,304,044,770,000,000,000,000,000.00$25,349$235.73+$2.2999277308531335e+25MIMTXW
9$44,643,905,199,991,210,000,000,000,000,000,000$44,619,295,973,271,085,000,000,000,000,000,000.00$28,325$237.94+$4.464390519999121e+28MIMTXW
10$80,992,190,441,907,720,000,000,000,000,000,000,000$80,944,421,463,343,720,000,000,000,000,000,000,000.00$31,624$239.96+$8.099219044190773e+31MIMTXW

IMTXW vs DGRO: Complete Analysis 2026

IMTXWStock

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401, which is in Phase 1b clinical trial; and IMA402 and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Full IMTXW Calculator →

DGROETF

The iShares Core Dividend Growth ETF seeks to track the investment results of an index composed of U.S. equities with a history of consistently growing dividends.

Full DGRO Calculator →
📬

Get this IMTXW vs DGRO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMTXW vs SCHDIMTXW vs JEPIIMTXW vs OIMTXW vs KOIMTXW vs MAINIMTXW vs VIGIMTXW vs NOBLIMTXW vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.